Inogen Inc. (NASDAQ:INGN) EVP Matt Scribner sold 4,551 shares of the firm’s stock in a transaction dated Wednesday, October 12th. The stock was sold at an average price of $59.45, for a total value of $270,556.95. Following the completion of the transaction, the executive vice president now directly owns 6,884 shares in the company, valued at approximately $409,253.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Matt Scribner also recently made the following trade(s):

  • On Monday, September 19th, Matt Scribner sold 4,551 shares of Inogen stock. The stock was sold at an average price of $60.18, for a total value of $273,879.18.
  • On Thursday, August 18th, Matt Scribner sold 2,320 shares of Inogen stock. The stock was sold at an average price of $56.39, for a total value of $130,824.80.
  • On Monday, July 18th, Matt Scribner sold 4,102 shares of Inogen stock. The stock was sold at an average price of $50.46, for a total value of $206,986.92.

Inogen Inc. (NASDAQ:INGN) opened at 56.18 on Monday. Inogen Inc. has a 12-month low of $28.81 and a 12-month high of $61.87. The firm’s 50-day moving average price is $59.16 and its 200 day moving average price is $52.07. The stock has a market cap of $1.13 billion, a PE ratio of 82.62 and a beta of 0.88.

Inogen (NASDAQ:INGN) last issued its earnings results on Thursday, August 4th. The medical technology company reported $0.25 EPS for the quarter, topping analysts’ consensus estimates of $0.20 by $0.05. Inogen had a return on equity of 9.50% and a net margin of 7.86%. The firm had revenue of $54.57 million for the quarter, compared to the consensus estimate of $52.44 million. During the same quarter in the prior year, the business earned $0.17 earnings per share. The company’s revenue was up 23.9% compared to the same quarter last year. Analysts anticipate that Inogen Inc. will post $0.63 EPS for the current year.

Insider Buying and Selling by Quarter for Inogen (NASDAQ:INGN)

Several hedge funds have recently modified their holdings of INGN. Brown Capital Management LLC bought a new stake in shares of Inogen during the second quarter worth approximately $60,117,000. BlackRock Fund Advisors increased its stake in shares of Inogen by 4.3% in the second quarter. BlackRock Fund Advisors now owns 1,058,168 shares of the medical technology company’s stock worth $53,025,000 after buying an additional 43,146 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Inogen by 24.5% in the second quarter. Vanguard Group Inc. now owns 891,757 shares of the medical technology company’s stock worth $44,686,000 after buying an additional 175,696 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Inogen by 28.7% in the second quarter. Dimensional Fund Advisors LP now owns 456,991 shares of the medical technology company’s stock worth $22,899,000 after buying an additional 101,922 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its stake in shares of Inogen by 4.8% in the first quarter. JPMorgan Chase & Co. now owns 444,075 shares of the medical technology company’s stock worth $19,975,000 after buying an additional 20,525 shares during the last quarter.

Several analysts recently issued reports on INGN shares. Zacks Investment Research raised Inogen from a “hold” rating to a “buy” rating and set a $67.00 target price on the stock in a research note on Tuesday, October 4th. Stifel Nicolaus downgraded Inogen from a “buy” rating to a “hold” rating in a research note on Friday, August 5th. They noted that the move was a valuation call. JPMorgan Chase & Co. lifted their target price on Inogen from $60.00 to $62.00 and gave the company an “overweight” rating in a research note on Friday, August 5th. Finally, Needham & Company LLC restated a “strong-buy” rating and set a $64.00 price target (up previously from $58.00) on shares of Inogen in a report on Sunday, August 7th. Three research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. Inogen has a consensus rating of “Buy” and an average target price of $58.50.

About Inogen

Inogen, Inc is a medical technology company. The Company is engaged in developing, manufacturing and marketing portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device weighing approximately 4.8 or seven pounds.

5 Day Chart for NASDAQ:INGN

Receive News & Stock Ratings for Inogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc. and related stocks with our FREE daily email newsletter.